Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Oral supplementation of histidine in patients with cognitive dysfunction should increase
brain anserine, carnosine and histamine levels which will result in improved cognition via
numerous proven in vivo mechanisms including increasing blood flow, neurogenesis,
angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid
protein, which is pathognomonic for Alzheimer's disease.
Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months.
Baseline evaluation and followup evaluation at 3 months postop.